10-Q: Dentsply Sirona Reports Q2 Loss Amid Impairments

Dentsply Sirona Inc. reported a significant net loss in Q2 2025, driven by substantial goodwill and intangible asset impairments, alongside declining net sales and cash flow from operations.

Summary

• Dentsply Sirona reported a net loss attributable to Dentsply Sirona of $45 million for the three months ended June 30, 2025, compared to a net loss of $4 million in the prior year period.
• For the six months ended June 30, 2025, the company recorded a net loss attributable to Dentsply Sirona of $25 million, a shift from a net income of $14 million in the same period of 2024.
• Net sales decreased by 4.9% to $936 million for the three months ended June 30, 2025, and by 6.3% to $1,815 million for the six months ended June 30, 2025, compared to the respective prior year periods.
• The company incurred pre-tax goodwill impairment charges of $156 million and intangible asset impairment charges of $79 million for the three and six months ended June 30, 2025.
• Cash provided by operating activities significantly decreased to $55 million for the six months ended June 30, 2025, from $233 million in the prior year period.
• The total net debt to total capitalization ratio increased to 51.0% at June 30, 2025, from 48.9% at December 31, 2024.
• The company issued $550 million in 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055, using proceeds to repay a $435 million bridge loan and for general corporate purposes.
• Restructuring efforts continue with the 2024 Plan targeting $80 million to $100 million in annual cost savings and a 2% to 4% global workforce reduction by the end of 2025, having incurred $30 million in charges to date.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant financial losses, substantial impairment charges, declining sales, and reduced cash flow from operations. While cost-saving initiatives and debt refinancing efforts are underway, the overall financial performance and the multitude of ongoing legal challenges and macroeconomic headwinds present a challenging outlook.

Positives

• Gross profit as a percentage of net sales increased to 52.4% for the three months ended June 30, 2025, up 50 basis points from 51.9% in the prior year, primarily due to lower manufacturing costs and favorable foreign currency translation.
• Selling, general, and administrative (SG&A) expenses decreased by $57 million (-14.5%) for the three months and $114 million (-14.0%) for the six months ended June 30, 2025, driven by lower headcount and advertising costs for Byte products, and other cost-saving initiatives.
• Research and development (R&D) expenses decreased, reflecting a disciplined approach while maintaining investment in digital workflow solutions and product development.
• Connected Technology Solutions segment adjusted operating income increased significantly by 231.0% for the three months and 274.0% for the six months ended June 30, 2025, due to lower headcount-related costs.
• Essential Dental Solutions segment adjusted operating income increased by 21.5% for the three months and 19.3% for the six months ended June 30, 2025, due to lower headcount and professional service costs, and higher net sales.
• The company successfully issued $550 million in new notes and repaid a $435 million bridge loan, demonstrating access to capital markets.
• Debt covenants were amended, and the company remains in compliance with these provisions as of June 30, 2025.
• A previously disclosed class action lawsuit (EDNY Court) reached a preliminary settlement of $84 million, with an offsetting insurance receivable of approximately $78 million, reducing the net legal expense to $6 million.

Negatives

• Net sales decreased across most segments and regions, with a notable 19.4% constant currency decline in Orthodontic and Implant Solutions for the three months ended June 30, 2025, primarily due to the suspension of Byte sales.
• The company reported a significant operating loss of $128 million for the three months and $65 million for the six months ended June 30, 2025, a substantial decline from operating income in the prior year periods.
• Goodwill and intangible asset impairments totaled $235 million for the three and six months ended June 30, 2025, reflecting reduced fair values due to tariffs, lower projected volumes, and competitive pressures.
• Net cash provided by operating activities decreased substantially to $55 million for the six months ended June 30, 2025, from $233 million in the prior year, primarily due to lower net sales and unfavorable changes in working capital (higher accounts receivable and inventory build).
• Days sales outstanding in accounts receivable increased to 59 days at June 30, 2025, from 55 days at December 31, 2024.
• Days of sales in inventory increased to 141 days at June 30, 2025, from 124 days at December 31, 2024.
• Interest expense, net, increased by 34.5% for the three months and 21.7% for the six months ended June 30, 2025, due to a higher average carrying balance of total borrowings.
• The company's operations in Russia face limitations on cash repatriation due to currency control measures, with $61 million of cash held in Russia as of June 30, 2025.

Risks

• Risk of future material goodwill and indefinite-lived intangible asset impairment charges if key assumptions, such as discount rates, revenue growth rates, or operating margins, decline further.
• Ongoing macroeconomic headwinds, including increasing uncertainties related to global trade policies, inflation, and potential recession, could continue to negatively impact global growth and consumer discretionary spending.
• The impact of tariffs and other trade protection measures, particularly on products imported from Europe and China, could increase costs and affect demand for products.
• Geopolitical conflicts, such as the Russia-Ukraine conflict and the Middle East conflict, could worsen, leading to further restrictions on operations, cash transfers, or sales.
• Failure to successfully renegotiate non-exclusive distribution agreements with Patterson Companies, Inc. or secure new agreements with other distributors could materially adversely affect business, operating results, and financial condition.
• The company is subject to multiple ongoing legal proceedings, including securities class actions and stockholder derivative suits, which could result in significant damages or legal fees.
• An ongoing IRS examination for tax years 2015 and 2016, if sustained, could result in additional federal income taxes and a loss of foreign tax credits.
• An investigation by the General Public Prosecutors Office Frankfurt am Main into intercompany loans could lead to unforeseen consequences, despite the company's belief in compliance with German laws.
• The ongoing implementation of a new global Enterprise Resource Planning (ERP) system could materially affect internal control over financial reporting.

Future Outlook

The company anticipates that challenging macroeconomic and market conditions, particularly in Germany, are likely to persist and may negatively impact sales of equipment in 2025. It expects to continue maintaining R&D investment at least 4% of annual net sales. The 2024 restructuring plan is expected to be substantially completed by the end of 2025, resulting in $80 million to $100 million in annual cost savings. The company expects to be able to finance operating cash requirements, capital expenditures (estimated $160 million to $190 million for full year 2025), and debt service from current cash, cash flows from operations, and existing borrowing facilities for the next twelve months. The company is currently assessing the implications of the One Big Beautiful Bill Act (OBBBA) signed into law on July 4, 2025, and will reflect the impact in future quarters, starting in Q3 2025.

Management Comments

• Management believes that sufficient liquidity is available in the United States and expects this to continue for the next twelve months.
• The company intends to vigorously defend all ongoing lawsuits, although it may elect to settle certain litigation matters.
• The company believes that the transactions at issue in the German investigation complied with all applicable German laws and intends to vigorously defend its positions.

Industry Context

The dental and healthcare industry faces global economic headwinds, including uncertainties related to trade policies, inflation, and potential recession, which are impacting consumer confidence and the ability of clinicians to finance equipment purchases. Europe, particularly Germany, is experiencing growth pressures and recessionary conditions, affecting equipment sales. Tariffs imposed by the U.S. government are increasing costs for imported products, especially dental equipment manufactured in Europe. Geopolitical conflicts in Russia-Ukraine and the Middle East, while not materially impacting overall operations, pose risks to financial stability and cash repatriation from certain regions. Competitive pressures are noted as a factor in lower volumes for premium equipment and implant products.

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action filed in the U.S. District Court for the Eastern District of New York (EDNY Court) regarding alleged securities law violations related to the 2016 merger and distributor inventory, which reached a preliminary settlement of $84 million in January 2025, with a final approval hearing scheduled for September 10, 2025.
• Securities Litigation consolidated in the U.S. District Court for the Southern District of New York (SDNY Court) alleging materially false and misleading statements regarding revenue recognition tied to distributor rebate and incentive programs, with class certification granted on July 10, 2025.
• Voluntary cooperation with the SEC following an internal investigation announced on May 10, 2022.
• Multiple stockholder derivative suits (Presura, Snee, Manfre) consolidated and stayed in the Delaware Court of Chancery, asserting claims against current and former directors and officers for breach of fiduciary duties, corporate waste, and insider trading related to revenue recognition and distributor inventory.
• The 2024 Securities Litigation (North Collier, Calvin, Key West) consolidated in the SDNY Court, alleging false and misleading statements regarding the performance of the Byte aligners business following its December 2020 acquisition, with a motion to dismiss the amended complaint filed on July 8, 2025.
• Stockholder derivative suits (OConnor, Andreotti) consolidated and stayed in the SDNY Court, with allegations similar to the 2024 Securities Litigation regarding breach of fiduciary duties and unjust enrichment related to the Byte LLC acquisition.
• A claim filed by Mr. Carlo Gobbetti in the Milan Chamber of Arbitration seeking 28 million EUR for alleged failure to pay a portion of a purchase price from a 2012 Share Purchase Agreement; the arbitral tribunal rejected the claims on July 22, 2024, but Mr. Gobbetti appealed on December 2, 2024, with a final appeal hearing scheduled for February 11, 2026.
• An ongoing IRS examination for U.S. federal income tax returns for 2015 and 2016, with a proposed adjustment that, if sustained, would result in additional federal income taxes on a $451 million distribution and a loss of foreign tax credits; the company is contesting this.
• An investigation by the General Public Prosecutors Office Frankfurt am Main into intercompany loans implemented in 2016 and 2017 as part of post-merger integration activities; no charges have been filed, and the company believes the transactions complied with German laws.

Stakeholder Impact

• Shareholders: Directly impacted by the net loss, decreased EPS, and significant impairment charges, which could negatively affect share price. The ongoing share repurchase program authorization could provide some support.
• Employees: Affected by ongoing restructuring plans (2024 Plan anticipates a 2% to 4% global workforce reduction) and potential changes in compensation structures due to incentive plan amendments.
• Customers: May experience impacts from competitive pricing strategies and potential changes in distribution arrangements, particularly with Patterson Companies, Inc.
• Creditors: Debt covenants were amended, and the company remains in compliance, which is positive for creditors, but increased net debt to capitalization ratio and higher interest expense could be a concern.
• Suppliers: The company is driving strategic procurement initiatives to leverage alternative sources of raw materials and transportation, which could impact existing supplier relationships.

Next Steps

• Final settlement approval hearing for the EDNY class action is scheduled for September 10, 2025.
• The 2024 Restructuring Plan is expected to be substantially completed by the end of 2025.
• The company will reflect the impact of the One Big Beautiful Bill Act (OBBBA) in future quarters, starting in the third quarter of 2025.
• The final hearing for the Carlo Gobbetti appeal proceedings is scheduled for February 11, 2026.
• The company continues to cooperate with the SEC regarding its internal investigation.
• The company intends to vigorously defend all ongoing lawsuits and pursue related appeals.
• The company continues to evaluate additional strategies to mitigate the impacts of tariffs and changes in trade policy.
• The company continues to monitor and evaluate the ongoing and potential impacts of geopolitical conflicts on its supply chain, costs, net sales, and profitability.
• The company continues to evaluate any further changes that could materially affect its internal control over financial reporting over the course of the new ERP system implementation.

Key Dates

Recommendation

The company's financial performance is significantly deteriorating, marked by a substantial net loss, operating loss, and large impairment charges. While cost-cutting and restructuring efforts are in progress, they are not yet offsetting the negative impacts of declining sales, competitive pressures, and adverse macroeconomic conditions. The increase in net debt and the decrease in cash from operations are concerning. Furthermore, the company faces a multitude of complex and costly legal proceedings, which introduce significant uncertainty and potential liabilities. Given these factors, the risk-reward profile appears unfavorable for investors at this time.

Keywords

Dental products, Dental technology, Dental equipment, SEC filing, 10-Q, Financial results, Goodwill impairment, Intangible assets, Net sales, Operating loss, Cash flow, Debt, Restructuring, Legal proceedings, Macroeconomic conditions, Tariffs, Orthodontics, Implants, CAD/CAM, Wellspect Healthcare, XRAY